Pharmaceuticals, Biotechnology & Life Sciences

Phio insider buying signals confidence amid biotech rally. Learn why executives’ purchases may boost value and what to watch for in its cancer immunotherapy pipeline.

Artiva insider trading: CMO Subhashis Banerjee’s 10b5‑1 buys and sells show steady confidence in the biotech’s growth, hinting at future upside for investors.

Inside Structure Therapeutics’ insider buying signals confidence, AI‑driven pipeline, and strategic partnerships that boost commercial strategy, market access and competitive positioning in biotech.

Adaptive Biotechnologies insider moves reveal executive confidence and a fast‑tracking TCR therapy pipeline, including KRAS‑G12C and COVID‑19 candidates, driving investor interest.

Halozyme’s CEO insider trades reveal disciplined 10b5‑1 strategy, backing strong growth in hyaluronidase delivery tech and value‑based payer wins.

Ne Mora Therapeutics insider trading shows confidence in its brain‑disease pipeline and disciplined liquidity strategy, hinting at future market‑access upside.

Discover why SEER Inc.’s CFO’s routine insider sales are tax‑efficient moves, not a warning signal, and what it means for investors.

Cypherpunk’s chief investment officer buys 16.6 million shares, backing the firm’s Zcash mining pivot and boosting its 31 % stake.

ATYR Pharma’s insider transfer by owner Bothe Roelof reveals a strategic shift in voting power and limited capital‑raising, impacting governance and future funding for its rare‑disorder drug pipeline.

MAPLIGHT THERAPEUTICS insiders buy 200k shares, signaling confidence in its Phase III immuno‑oncology lead and future market positioning.